ELEM Biotech

www.elem.bio ↗ ·Barcelona ·Seed

ELEM Biotech is a Barcelona-based biosimulation company that builds healthcare digital twins, computational models of human organs used to run in silico (virtual) trials for pharmaceutical companies, contract research organisations, medical device manufacturers and regulators. Its cloud platform V.HEART Trials lets users set up, run and analyse virtual clinical trials, and V.HEART Discovery flags drug candidates at risk of QT prolongation in humans. The company reports more than 15,000 digital twin studies completed. Its core technology is based on the Alya multi-physics simulation code. It was founded in 2018 as a spin-off of the Barcelona Supercomputing Center (BSC), UPC and CSIC, and also has an office in Bristol. ELEM has raised seed funding through Capital Cell and Namarel Ventures, along with European Innovation Council (EIC) grant funding.

Founded

2018

Founders

Total funds raised

€1.2M

SectorsHealthtech, Biotech, Digital twins, In silico clinical trials, Biosimulation Start-up MapHealthtech & Bio › R&D tools & software for life sciences

Suggest a correction

Founders

Christopher Morton

Co-Founder & CEO

Guillaume Houzeaux

Co-Founder

José María Cela

Co-Founder

Mariano Vázquez

Co-Founder & CTO

Global models 5

Unlearn

United States · www.unlearn.ai ↗

Sells AI-built digital twins of patients to pharma companies so they can run smaller, partly virtual clinical trials, which is the same in silico trial offer aimed at the same buyers.

$135MComparable

Aitia

United States · aitiabio.com ↗

Builds causal 'Gemini' digital twins of human disease biology and sells simulation-driven drug discovery and development to pharma partners.

$100MComparable

Turbine

Hungary · turbine.ai ↗

Offers a simulation platform of virtual cells that pharma companies use to run in silico experiments and predict drug response before lab and clinical work.

$45MComparable

Nova

France · www.novainsilico.ai ↗

Runs knowledge-based computational disease models and virtual patient populations to deliver in silico clinical trials for pharma and biotech clients.

$25MComparable

VeriSIM Life

United States · www.verisimlife.com ↗

Sells a hybrid AI and physiological simulation platform (BIOiSIM) that predicts how drug candidates behave in humans, including safety risk, for pharma companies.

$20MComparable

In the same niche 26 others

See all in the Start-ups Map →

No stage disclosed · €4.2M

+20 more →

Notes: Most funded first

Investors 4

Open as list →

Roger Assaker

Seed 2021 Luxembourg

Funding rounds 1

Date	Round	Amount	Lead
2021-12-17	Seed (estimated)	approximately €1.2M	Lead not disclosed +3 more

News 6

Open as list →

Published	Article
2025-10-01	Expanding Digital Twins Use from Biopharma to Virtual Human Development ↗ GEN - Genetic Engineering & Biotechnology News 2025-10-01
2024-06-17	From scan to simulation: Engineering my heart's digital twin using supercomputing technology ↗ Womanthology 2024-06-17
2024-03-21	How Digital Twins' Virtual Realities Will Transform The World ↗ Noema Magazine 2024-03-21
2024-03-18	Es argentino y desarrolló en Barcelona un sistema para hacer una réplica digital de tu corazón para prevenir enfermedades ↗ La Nación 2024-03-18
2024-01-23	ELEM Biotech establishes its headquarters at Tech Barcelona's Pier07 ↗ Tech Barcelona 2024-01-23
2023-11-07	First engineer to model their own heart reveals simulation at Science Museum ↗ Science Museum (press release) 2023-11-07